Movement Alert｜Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63

Market Focus05-28

On May 28, Intellia Therapeutics rose 8.01% in regular trading, trading at $13.63 USD/share, with trading volume of $72.34 million.

Within the Biotechnology sector where Intellia Therapeutics belongs, the overall sector performance was mixed. Among individual stocks, Regeneron Pharmaceuticals down 0.39%, AbbVie up 1.09%, Amgen up 0.44%, Vertex Pharmaceuticals up 0.67%, Gilead Sciences up 0.02%.

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. Its pipeline includes NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease, along with programs in hemophilia and engineered cell therapies for cancers and autoimmune diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115630404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 03:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115630404","market":"us","top_or_hot":-1,"title":"Movement Alert｜Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63","media":"Market Focus","content":"<p><p>On May 28, Intellia Therapeutics rose 8.01% in regular trading, trading at $13.63 USD/share, with trading volume of $72.34 million.</p><p>Within the Biotechnology sector where Intellia Therapeutics belongs, the overall sector performance was mixed. Among individual stocks, Regeneron Pharmaceuticals down 0.39%, AbbVie up 1.09%, Amgen up 0.44%, Vertex Pharmaceuticals up 0.67%, Gilead Sciences up 0.02%.</p><p>Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. Its pipeline includes NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease, along with programs in hemophilia and engineered cell therapies for cancers and autoimmune diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 03:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, Intellia Therapeutics rose 8.01% in regular trading, trading at $13.63 USD/share, with trading volume of $72.34 million.</p><p>Within the Biotechnology sector where Intellia Therapeutics belongs, the overall sector performance was mixed. Among individual stocks, Regeneron Pharmaceuticals down 0.39%, AbbVie up 1.09%, Amgen up 0.44%, Vertex Pharmaceuticals up 0.67%, Gilead Sciences up 0.02%.</p><p>Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. Its pipeline includes NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease, along with programs in hemophilia and engineered cell therapies for cancers and autoimmune diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1115630404","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115630404","pubTimestamp":1779910573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, Intellia Therapeutics rose 8.01% in regular trading, trading at $13.63 USD/share, with trading volume of $72.34 million.Within the Biotechnology sector where Intellia Therapeutics belongs,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"走势提示|Intellia Therapeutics常规交易上涨8.01%，报13.63美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"On May 28, Intellia Therapeutics rose 8.01% in regular trading, trading at $13.63 USD/share, with trading volume of $72.34 million.Within the Biotechnology sector where Intellia Therapeutics belongs, the overall sector performance was mixed. Among individual stocks, Regeneron Pharmaceuticals down 0.39%, AbbVie up 1.09%, Amgen up 0.44%, Vertex Pharmaceuticals up 0.67%, Gilead Sciences up 0.02%.Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. Its pipeline includes NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease, along with programs in hemophilia and engineered cell therapies for cancers and autoimmune diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115630404","isCrawlerRequest":true}